A New Plausible Link between Lysophosphatidylcholine, TGF-β, and Fibromuscular Dysplasia.
M. Shimabukuro
DOI: https://doi.org/10.5551/jat.ED040
2016-06-01
Journal of Atherosclerosis and Thrombosis
Abstract:Fibromuscular dysplasia (FMD) is a relatively rare and non-atherosclerotic disease of medium-sized vessels that was originally described in 1938. It is characterized by arterial dysplasia and obstruction to arterial blood flow caused by neointimal lesions rich with cells that have smooth muscle phenotype. Patients with FMD can present with arterial stenosis, beading, dissection, and aneurysm. In the US Registry for FMD cohort , nearly 80% of registrants had renal FMD (presenting as hypertension), and almost three-quarters had carotid FMD (presenting as stroke or transient ischemic attack). Vertebral FMD was the third most common condition (36.6%). Other reported sites of involvement include the mesenteric arteries, iliac arteries, intracranial vessels, and upper extremity (brachial) arteries . Incidences of FMD are more common among females, accounting for approximately 90% of the adult cases. Although FMD was thought to be a disease in young women, recent studies revealed that older individuals account for a large proportion of the total affected patients . High prevalence of aneurysms (23.5%), sudden death (19.8%), and stroke (53.5%) among firstand second-degree family members in the US Registry suggests that FMD may represent an inherited systemic arteriopathy with diverse clinical phenotype . However, the genetic and biological determinants of FMD have been largely unknown. The recent report by Tanaka, et al. may provide an insight into the underlying mechanism(s) of FMD. The authors compared the distribution of lipid molecules, between atherosclerotic visceral artery aneurysms (VAAs) and FMD-associated VAAs, using an emerging technique called matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) . This method can distinguish various types of lipid molecules, such as phospholipids, neutral lipids, glycolipids, and fatty acids, at the molecular species level in each arterial layer. The authors found a characteristic distribution of cholesterol esters in the intima and media of atherosclerotic VAAs, which was negligible in FMD-associated VAAs. By contrast, lysophosphatidylcholine (lysoPC) accumulated in the medial ridge of the adventitia in the aneurysmal sac and the adjacent arteries of patients with FMD-associated VAAs. LysoPC accumulated mainly in the area of intimal hyperplasia in atherosclerotic VAAs and the adjacent arteries. Although overlapping features between FMD and vascular connective tissue diseases, such as LoeysDietz syndrome or the vascular type of Ehlers-Danlos syndrome, have been suggested, the prevalence of genetic mutations associated with connective tissue disease was negligible in a cohort of FMD patients . In the cohort, two FMD patients with a history of arterial dissection and aortic ectasia or aneurysm showed distinct novel point mutations in transforming growth factor (TGF)-β receptor type 1 gene. Ganesh et al. found that plasma levels of circulating TGF-β1 and TGF-β2 and secretion of both factors by fibroblasts were increased in FMD patients than in the matched controls. LysoPC, with one mole of fatty acid per mole of lipid in the sn -1 position, is produced by the hydrolysis of dietary and biliary phosphatidylcholine, but it is also formed in most tissues via hydrolysis of phosphatidylcholine by the phospholipase A2 enzyme superfamily as part of the de-acylation/re-acylation cycle. Though stearoyl-lysoPC shows an anti-inflammatory role, lysoPC has proinflammatory properties and is known to be a pathological component of oxidized lipoproteins (LDL) that is found in the plasma and atherosclerotic lesions. LysoPC is thought to be a mediator of TGF-β activation. Although it is currently unclear whether the A New Plausible Link between Lysophosphatidylcholine, TGF-β, and Fibromuscular Dysplasia